Antares Pharma — Shareholder Meeting (June 2004)
53 slides from Antares Pharma's shareholder meeting presentation, Jun 22, 2004
Slide 1: Annual Meeting of Shareholders
Exhibit 99.1 Antares Pharma, Inc. Annual Meeting of Shareholders June 22, 2004 New Balance between Corporate Partnering and Specialty Pharma
Slide 2: Safe Harbor Statement
Safe Harbor Statement Throughout this presentation, we discuss some of our expectations regarding the Company’s future performance. All of these forward-looking statements are based on our current views and assumptions. Actual results could differ materially from these current expectations and from
Slide 3: Agenda
Agenda Overview Technology Platforms Business Opportunities Refined Strategy – Corporate Partnering – Specialty Pharma Goals & Accomplishments Financial Information
Slide 4: Company Summary
Company Summary Formed January 2001 2003 sales of $3.8 million / $5.6 million gross Cash position approximately $14 million No debt 28 full-time staff Three locations: Basel, Switzerland Minneapolis, Minnesota Exton, Pennsylvania
Slide 5: Statement of Operations
Statement of Operations Gross Revenue (Billed & Accrued) & GAAP Revenue $ M 7 6 5 4 3 2 1 0 2001 2002 2003 3.402 3.499 4.112 3.996 5.603 3.787
Slide 6: 2003 Goals and Results
2003 Goals and Results Two major partnerships – Result: Only one Outsource device assembly activities and refocus on research and development – Result: Accomplished April 2003 Restructure debt financing – Result: Eliminated all debt September 2003 Retain investment banker – Result: SCO retained July
Slide 7: Accomplishments—2003
Accomplishments—2003 December - Milestone Payment from Lilly October - Positive Results from Phase II Trial of LibiGel™ September - License Agreement with Lilly - Conversion of all Debt to Equity July - Raised $4.0 Million in Private Equity Placement May - Phase II/III Trial for Estradiol Topical Ge
Slide 8: Statement of Strategic Intent—2001
Statement of Strategic Intent—2001 Near-term: Partner with global pharmaceutical and biotechnology companies to provide solutions to their drug delivery needs Intermediate-term: Add the capability to carry products further along the value chain before licensing Longer-term: Build capability to comme
Slide 9: Strategy
Strategy Accelerate in-house specialty pharma company focus Aggressively engage new partnering opportunities Expand opportunities with existing partners
Slide 10: Strategy Overview
Strategy Overview Antares Specialty Pharma Products Goal: Sales & Operating Profits Antares Corporate Partner Products Goal: Milestones & Royalties CORE TECHNOLOGIES Transdermal Gels (ATD™ Technology) Fast-Melt Tablets (Easy Tec™) Disposable, Single-Use Mini-Needle Injection Device (Vibex™) Reusable
Slide 11: Technology: Transdermal Gels (ATD)
Technology Transdermal Gels (ATD™ Technology) The future of transdermal delivery Patented technology Cosmetic elegance Safe ingredients Innovative packaging Opportunity Hormone therapy products in Phase II and Phase III trials Non hormonal products in development Royalty revenue anticipated in 2006
Slide 12: Technology: Fast-Melt Tablet (Easy Tec)
Technology Fast-Melt Tablet (Easy Tec™) Patented technology Low cost, conventional manufacturing process Opportunity Approximately $1.5 billion market growing at 20% per year Meets needs of changing demographics Antares product revenue generation by 2006
Slide 13: Technology: Mini-Needle Injection System (Vibex)
Technology Mini-Needle Injection System (Vibex™) Low cost, single-use device Hidden needle never exposed to patient No sharps disposal issues Opportunity Emergency, acute care or intermittent use Extendable to vaccinations Proven in extensive clinical trials Potential revenue generation in late 2005
Slide 14: Technology: Reusable Needle-Free Injectors
Technology Reusable Needle-Free Injectors (VISION®, Valeo™) VISION® currently marketed for use with insulin and human growth hormone Readily adapted for many injectable products Easy to use, fast injection, no sharps disposal issues Opportunity Licensing agreement with Lilly for diabetes and obesity
Slide 15: Independent Industry Projections: Needle-Free Sector
Independent Industry Projections Needle-Free Sector (in Millions) 450 400 350 300 250 200 150 100 50 0 2002 2007 $10.3 $425 $195 $230 all other 46% insulin 54% Source: Greystone Associates Needle-Free Injection, June 2003
Slide 16: Independent Industry Projections: Vaccine Market
Independent Industry Projections Worldwide Vaccine Market 6 4 2 0 2002 2007 Prophylactic Therapeutic Source: Greystone Associates Needle-Free Injection, June 2003
Slide 17: Independent Industry Projections: Transdermal Delivery
Independent Industry Projections Transdermal Delivery Market US$ (Billions) 14 12 10 8 6 4 2 0 2002 2005 Source: Jain PharmaBiotech – November 2002
Slide 18: Independent Industry Projections: Fast-Melt Sector
Independent Industry Projections Fast-Melt Sector $ (billions) 3.00 2.50 2.00 1.50 1.00 0.50 0.00 2002 2003 2004 2005 2006 2.49 2.07 1.73 1.44 1.20 Source: Technology Catalysts International—2003
Slide 19: Established Corporate Partners
Established Corporate Partners
Slide 20: Corporate Partnered ATD Products
Corporate Partnered ATD™ Products Formulation Development Preclinical Testing Clinical Phase I / II Clinical Phase III Regulatory Submission Commercialization Ibuprofen Gel Estradiol Patch Estradiol Gel Estradiol + Progestin Testosterone for FSD Testosterone for male hypogonadism NPMG collaboration
Slide 21: Device Products
Device Products Concept Prototype for Clinical Evaluation Design Finalization Manufacturing Scale-Up Regulatory Submission Commercialization Vision for Insulin Vision for hGH Valeo for Insulin Vibex Platforms AJ1 AJ2 AJ3 AJ4 AJID © 2004 Antares Pharma
Slide 22: Corporate Partnering Business Model
Corporate Partnering Business Model Licensing Fees Scale-Up Costs Milestone Payments Manufacturing Margins Royalties on Sales * Devices $0.2-10m Typically paid by partner $2.0-10m 20-40% 2-5% Gels $0.1–10m As above $1.0-15m N/A 4-15% * Dependent on stage of licensing
Slide 23: Examples of Major Corporate Partnerships
Examples of Major Corporate Partnerships - - - - - - - - From Year of Introduction - - - - - - - - Million USD Year 1 Year 2 Year 3 Year 4 Year 5 Diabetes (Valeo™) 11 23 25 28 30 Female Sexual Dysfunction (ATD™) 10 12 14 16 18
Slide 24: Future Opportunities – Corporate Partner Products
Future Opportunities – Corporate Partner Products Transdermal gels – Projected to be major driver in transdermal sector Source: Frost & Sullivan, 2003 Fast-melt technology – Approximately $1.5 billion market growing at 20% per year Injection devices – Biotechnology products require less invasive way
Slide 25: Targeted Therapeutic Protein Opportunities
Targeted Therapeutic Protein Opportunities Segment/Class 2002 Sales (billion USD) Erythropoietins 8.4 Interferons 5.7 Insulin 4.4 Monoclonal Antibodies 4.2 Blood Factors 3.6 Colony Stimulating Factors 2.7 Growth Hormones 2.7 Interleukins 1.7 Growth Factors 0.2 Therapeutic Vaccines 0.07 Others (calci
Slide 26: Specialty Pharma Products
Specialty Pharma Products Formulation Development Preclinical Testing Clinical Phase I / II Phase III (where necessary) Regulatory Submission Commercialization Oxybutynin ATD™ Alprazolam ATD™ *Estradiol ATD™ *Testosterone ATD™ for FSD Ibuprofen Gel Ibuprofen Easy Tec™ Acetaminophen Easy Tec™ Loperam
Slide 27: Specialty Pharma Teaming Model
Specialty Pharma Teaming Model R&D Manufacturing /Filling Clinical Development Regulatory Commercialization Company A (in discussion) Easy Tec™ Company C (in discussion) Gels CSO Company A (in discussion) Company B (in discussion) Devices © 2004 Antares Pharma ©2004 CONFIDENTIAL
Slide 28: Examples of Specialty Pharma
Examples of Specialty Pharma - - - - - - - - From Year of Introduction - - - - - - - - Million USD Year 1 Year 2 Year 3 Year 4 Year 5 Female Sexual Dysfunction (ATD™) – Europe, Japan 30 38 45 53 61 Fast-Melt Tablet (Easy Tec™) 4 11 19 23 25
Slide 29: Future Opportunities – Specialty Pharma Products
Future Opportunities – Specialty Pharma Products Continuing development of portfolio products Addition of further generic opportunities with focus on short-term return Partner with manufacturing/clinical development organizations to minimize Antares’ costs
Slide 30: Company Goals for 2004
Company Goals for 2004 Secure capital to support strategy – Result: Completed $15.1m equity financing in March Minimum of two additional corporate partnerships Re-establish national share listing Create greater investor awareness – Result: Completed IR/MR team in April Increase revenues from existin
Slide 31: Accomplishments – YTD 2004
Accomplishments – YTD 2004 March - Japanese Licensee, JCR Pharmaceuticals Co. Ltd, Obtained Approval for VISION® for Use With Human Growth Hormone - U.S. Patent on Valeo™, Needle-Free Device Technology - Completed Phase I Trial for Oxybutynin Topical Gel February - Received U.S. Patent on Easy Tec™
Slide 32: Summary
Summary Revenue from own specialty pharma products starting in 2006 Additional royalty income from corporate business partnerships in 2006 Technology platforms meet the needs of pharmaceutical/biotechnology partners in growth areas Financing sufficient to advance our plans
Slide 33: Financial Overview
Financial Overview Balance Sheet Equity Position Revenue Breakdown Operations 2001 through 2003 Operations 1Q04
Slide 34: Major Balance Sheet Data
Major Balance Sheet Data $ M 2001 2002 2003 1Q04 Cash 1.965 .268 1.929 15.080 Other assets 9.163 6.141 4.026 3.996 Total assets 11.128 6.409 5.955 19.076 Liabilities 3.660 4.538 2.090 2.235 Deferred Revenue 1.511 1.216 3.558 3.319 Equity 7.468 .655 .307 13.523 Total Liabilities & Equity 11.128 6.409
Slide 35: Equity Information
Equity Information Shares outstanding approximately 38 million Fully diluted approximately 61 million – 17.3 million warrants exercisable between $0.55 and $29.55 – 2.1 million stock options exercisable between $1.56 and $23.00 – 1.2 million shares Convertible Series A Preferred – 2.4 million shares
Slide 36: 2003 Gross Revenue Distribution
2003 Gross Revenue Distribution Development 6.5% Lic & Fees 43.8% Royalties 2.4% Sales 47.2% Insulin 13.6% hGH 86.4%
Slide 37: Statement of Operations: Product Sales, Development Fees
Statement of Operations Product Sales Development Fees $ M $ M 3 2.5 2 1.5 1 0.5 0 2001 2002 2003 1 0.8 0.6 0.4 0.2 0 2001 2002 2003 2.015 20% 2.422 9% 2.647 0.754 24% 0.935 61% 0.365
Slide 38: Statement of Operations: Licensing Fees, Royalties
Statement of Operations Licensing Fees & Milestone Payments Royalties $ M $ M 2.5 2 1.5 1 0.5 0 2001 2002 2003 0.632 19% 0.754 226% 2.456 0.25 0.2 0.15 0.1 0.05 0 0 0 0.135 2001 2002 2003
Slide 39: Statement of Operations: Gross and GAAP Revenue
Statement of Operations Gross Revenue (Billed & Accrued) & GAAP Revenue $ M 7 6 5 4 3 2 1 0 Gross Revenue GAAP Revenue 2001 2002 2003 3.402 3.499 4.112 3.996 5.603 3.787
Slide 40: Statement of Operations: Operating Expenses
Statement of Operations Operating Expenses 12 10 8 6 4 2 0 11.206 4% 11.684 11% 10.413 2001 2002 2003
Slide 41: Statement of Operations: Net Loss, Operating Loss
Statement of Operations Net Loss Operating Loss 0 -2 -4 -6 -8 -10 -12 0 -10 -20 -30 -40 -9.571 7% -8.634 16% -10.262 -9.499 22% -11.609 9% 183% -10.574 -22.244 -32.818 2001 2002 2003 2001 2002 2003
Slide 42: Statement of Operations-1Q04: Revenue
Statement of Operations-1Q04 Gross Revenue (Billed & Accrued) & GAAP Revenue $ M Gross Revenue GAAP Revenue 2.5 2 1.5 1 0.5 0 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 0.838 0.669 2.124 0.91 0.617 0.726
Slide 43: Statement of Operations-1Q04: Losses
Statement of Operations-1Q04 Operating Loss Net Loss 0 -0.5 -1 -1.5 -2 -2.5 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 0 -0.5 -1 -1.5 -2 -2.5 -3 -3.5 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 -2.159 11% -1.916 5% -1.823 -2.147 4 1% -3.017 37% -1.894
Slide 44: Financial Summary
Financial Summary Cash to advance strategy No debt Deferred revenue of $3.3m Shareholders’ equity of $13.5m Increasing gross revenues Operational efficiencies & reduced cost Foundation for the future
Slide 45: hee antares (©2006 Antares Pharma
as hee 7 antares (©2006 Antares Pharma
Slide 46: Supplemental Information
Supplemental Information 7 antares
Slide 47: Presentations and Publications
Presentations and Publications June 2004 - BIO 2004 – San Francisco - FBR 8th Annual Growth Investor Conference – New York May 2004 - AAPS Workshop on Drug Delivery Devices – Boston - Technology Catalysts 21st Annual International Technology Transfer Forum – Washington DC April 2004 - Investor Lunch
Slide 48: Press Coverage
Press Coverage Investor’s Business Daily – June 14, 2004 – “Biotech companies look for the differentiation of their products through the use of innovative devices.” – “Antares landed a formidable ally when it entered into a licensing deal with pharmaceutical giant Eli Lilly.” Philadelphia Business J
Slide 49: Press Coverage (continued)
Press Coverage (continued) Philadelphia Business Journal – May 9-13, 2003 – “There’s a general agreement that technology has advanced to the point that someday in the future, needles will be scientific curiosities relegated to a museum somewhere.” Daily Local News – April 6, 2003 – “Not taking medic
Slide 50: Statement of Operations-1Q04: Product Sales, Development Fees
Statement of Operations-1Q04 Product Sales Development Fees $ M $ M 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 0.442 54% 0.679 31% 0.471 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 0.14 0.12 0.1 0.08 0.06 0.04 0.02 0 0.096 73% 0.025 308% 0.102
Slide 51: Statement of Operations-1Q04: Licensing Fees, Royalties
Statement of Operations-1Q04 Licensing Fees & Milestone Payments Royalties $ M $ M 1.4 1.2 1 0.8 0.6 0.4 0.2 0 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 0.3 358% 1.375 98% 0.024 0.05 0.04 0.03 0.02 0.01 0 0 0.045 58% 0.019 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004
Slide 52: Statement of Operations-1Q04: Total Revenue
Statement of Operations-1Q04 Total Revenue (Billed & Accrued) $ M 2.5 2 1.5 1 0.5 0 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 0.838 153% 2.124 71% 0.617
Slide 53: Statement of Operations-1Q04: Operating Expenses
Statement of Operations-1Q04 Operating Expenses 3 2.5 2 1.5 1 0.5 0 1st Qtr 2002 1st Qtr 2003 1st Qtr 2004 2.167 7% 2.324 5% 2.203